Enhancing hemopoietic drug resistance: a rationale for reconsidering the clinical use of mitozolomide.
about
Clinical and histological features of idiosyncratic acute liver injury caused by temozolomide.Phase I study of fotemustine in pediatric patients with refractory brain tumors.Biological effects of novel "combi-targeting" molecule and its effect on DNA repair pathway in hormone-refractory prostate cancerLive and let die: in vivo selection of gene-modified hematopoietic stem cells via MGMT-mediated chemoprotection
P2860
Enhancing hemopoietic drug resistance: a rationale for reconsidering the clinical use of mitozolomide.
description
2000 nî lūn-bûn
@nan
2000 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Enhancing hemopoietic drug res ...... clinical use of mitozolomide.
@ast
Enhancing hemopoietic drug res ...... clinical use of mitozolomide.
@en
type
label
Enhancing hemopoietic drug res ...... clinical use of mitozolomide.
@ast
Enhancing hemopoietic drug res ...... clinical use of mitozolomide.
@en
prefLabel
Enhancing hemopoietic drug res ...... clinical use of mitozolomide.
@ast
Enhancing hemopoietic drug res ...... clinical use of mitozolomide.
@en
P2093
P356
P1433
P1476
Enhancing hemopoietic drug res ...... clinical use of mitozolomide.
@en
P2093
Chinnasamy D
Chinnasamy N
Fairbairn LJ
Lashford LS
Rafferty JA
P2888
P304
P356
10.1038/SJ.CGT.7700120
P577
2000-02-01T00:00:00Z